AKBA Research and Charts

AKBA - Akebia Therapeutics Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2024-08-09 (Delayed quote data 2025-04-04)

Last 1.77	Change ⇓ -0.11 (-5.85%)	Volume 6,501,587
	Open 1.83	High 1.85	Low 1.71

8EMA (Daily) 1.91	40EMA (Daily) 2.00	50EMA (Daily) 1.99	STO (Daily) 16.293	MACD Hist (Daily) -0.066
8EMA (Weekly) 1.965	40EMA (Weekly) 1.77	50EMA (Weekly) 1.71	STO (Weekly) 39.749	MACD Hist (Weekly) -0.079


Company Profile
Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.